Webinar Recording: Let’s talk about value: Use RWE to determine drug price and performance

FREE WEBINAR | Tuesday 3rd December | 2:30 – 3.30pm GMT / 9.30 – 10.30am EST

This webinar brought together pharma, US payers, and global HTA bodies to investigate how real-world evidence (RWE) is being used to inform questions of drug value and effectiveness. We’ll explore best practices for determining drug pricing and value using RWE, what this means for your evidence generation strategy, and consider how we can solve the risk-sharing equation to bring the required treatments to patients who need them most – at an affordable rate! 

You’ll learn how: 

  • Payers and HTA agencies are updating assessment frameworks to incorporate RWE and how this will impact manufacturer evidence generation  
  • To leverage RWE across the drug life cycle to meet the growing demand for effectiveness evidence
  • How principled database epidemiology is challenging the traditional evidence hierarchy

Panelists include:
Eddie Lee

Eddie Lee

Head of US HEOR Strategy

UCB

Dr. Pamela Bradt

Dr. Pamela Bradt

Chief Science Officer

ICER

Carolyn Magill

Carolyn Magill

CEO

Aetion

Enkeleida Nikai-Fitzgerald

Enkeleida Nikai-Fitzgerald

Head of Real-World Evidence, Senior Director

Janssen EMEA

Moderator:
Paul Simms

Paul Simms

Chairman

eyeforpharma